Usage: Targretin (bexarotene) capsules treat skin manifestations of cutaneous T-cell lymphoma in patients who have not responded to at least one prior systemic therapy.
Usage: Targretin gel 1% treats cutaneous lesions in CTCL (Stage IA and IB) patients whose disease has not responded to or was not tolerated by other therapies.